Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2026-08-19 17:00:11 ET · period of report 2026-08-18 · accession 0001995218-26-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-19 17:00 | 2026-08-18 | LXEO | Townsend Richard Nolan | CEO, Dir | S - Sale | $4.95 | -3,345 | 374.5K | -0.9% | -$16.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-18 | S | D | 3,345 | $4.95 | 374,472 | D | — | — | (F1) Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). (F2) This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 242,911 Restricted Stock Units. |